|
Market Closed -
NYSE
16:00:02 2026-09-22 EDT
|
5-day change | 1st Jan Change | ||
| 1.230 USD | +9.82% |
|
+12.84% | -65.16% |
| 08-14 | ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says | MT |
| 08-13 | ADC Therapeutics SA, Q2 2026 Earnings Call, Aug 13, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 143M | - | - | - | ||
| 74.33B | |||||
| 62.26B | |||||
| 27.72B | |||||
| 26.42B | - | ||||
| 24.62B | - |
- Stock Market
- Stocks
- ADCT Stock
- Charts ADC Therapeutics SA
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
